Textbook of Personalized Medicine - Second Edition [2015]

122 in Canada, and the data from the pharmacogenomic study will help support regula- tory fi lings for the combined use of the t ...

123 With >1 million patients undergoing coronary stenting per year in the US, this extrapolates to >14,000 stent thrombosi ...

124 located within SLCO1B1 on chromosome 12, what is strongly associated with an increased risk of statin-induced myopathy. SLCO ...

125 The SAEC is not the only federal initiative aimed at improving drug safety. The Critical Path is also linking the Associatio ...

126 Therapeutic Drug Monitoring, Phenotyping, and Genotyping Therapeutic drug monitoring (TDM) has been used for over three deca ...

127 Comprehensive phenotyping is important for understanding disease mechanisms and variations in disease course and response to ...

128 Genotyping Genotyping also predicts metabolic capacity but involves identifi cation of defi ned genetic mutations that give ...

129 The term ‘phenomics’ is coined to describe, in anticipation, the new fi eld that is likely to form from the behavioral and o ...

130 Limitations of Genotype-Phenotype Association Studies Although genotype-phenotype association studies are seemingly simple, ...

131 Increasingly, genetic polymorphisms of transporter and receptor systems are also recognized as causing interindividual varia ...

132 will enable physicians to identify adverse effects from drugs used to treat HIV/ AIDS, hepatitis, and other infectious disea ...

133 reduction in adverse drug reactions, improved outcome and cost-effectiveness. There are two approaches to application of pha ...

134 Clinical Implications of Pharmacogenetics Application of CYP450 Genotyping in Clinical Practice The polymorphic nature of th ...

135 Table 4.9 Pharmacogenomic biomarkers in drug labeling Drug Therapeutic area Gene Referenced subgroup Abacavir Infectious dis ...

136 Table 4.9 (continued) Drug Therapeutic area Gene Referenced subgroup Chlorpropamide Endocrinology G6PD G6PD defi cient Cispl ...

137 Table 4.9 (continued) Drug Therapeutic area Gene Referenced subgroup Fluorouracil (1) Dermatology DPYD DPD defi cient Fluoro ...

138 Table 4.9 (continued) Drug Therapeutic area Gene Referenced subgroup Mipomersen Endocrinology LDLR Homozygous familial hyper ...

139 Table 4.9 (continued) Drug Therapeutic area Gene Referenced subgroup Propafenone Cardiology CYP2D6 CYP2D6 poor metabolizers ...

140 expression in some of the polymorphic enzymes are of interest to the practicing physicians. The clinical signifi cance of ge ...

141 Use of Pharmacogenetics in Clinical Pharmacology Application of CYP2C19 Pharmacogenetics Epigenomics and Personalized Medici ...